A5059089207- Cardiac Imaging and Diagnostics
- Lipoproteins and Cardiovascular Health
- Cardiovascular Function and Risk Factors
- Coronary Interventions and Diagnostics
- Cardiovascular Disease and Adiposity
- Advanced MRI Techniques and Applications
- Acute Myocardial Infarction Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cardiac Valve Diseases and Treatments
- Cardiovascular Health and Disease Prevention
- Atrial Fibrillation Management and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Treatment and Management
- Open Education and E-Learning
- Infective Endocarditis Diagnosis and Management
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer, Lipids, and Metabolism
- Cerebrovascular and Carotid Artery Diseases
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac electrophysiology and arrhythmias
- Blood Pressure and Hypertension Studies
- Heart Failure Treatment and Management
- Cardiac Arrhythmias and Treatments
- Pharmaceutical Economics and Policy
- Tissue Engineering and Regenerative Medicine
Monash University
2020-2025
Royal Adelaide Hospital
2015-2025
South Australian Health and Medical Research Institute
2015-2025
The University of Adelaide
2015-2025
Central Adelaide Local Health Network
2017-2025
Government of Western Australia Department of Health
2021-2025
Women's and Children's Health Network
2024-2025
University of Arizona
2022-2025
Monash Health
2022-2024
Clinical Research Institute
2019-2024
High-sensitivity troponin assays promise earlier discrimination of myocardial infarction. Yet, the benefits and harms this improved discriminatory performance when incorporated within rapid testing protocols, with respect to subsequent clinical events, has not been evaluated in an in-practice patient-level randomized study. This multicenter study noninferiority a 0/1-hour high-sensitivity cardiac T (hs-cTnT) protocol comparison 0/3-hour masked hs-cTnT patients suspected acute coronary...
The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men prostate cancer and known atherosclerotic disease remains controversial.In this international, multicenter, prospective, randomized, open-label trial, concomitant were randomly assigned 1:1 to receive the antagonist degarelix or agonist leuprolide for 12 months. primary outcome was time first adjudicated major adverse event (composite death, myocardial infarction,...
Importance Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused clinical practice. Objective To assess the effect of a coordinated, multifaceted intervention assessment, education, and feedback vs usual care on proportion prescribed all 3 groups recommended, evidence-based (high-intensity statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], sodium-glucose cotransporter [SGLT2]...
The University of Adelaide offers a six-year undergraduate medical degree with focus on small group learning. Senior students had previously received limited formal training in education skills, and were identified as an underutilised teaching resource.To devise programme which senior are exposed to the various facets university responsibilities evaluate its impact both tutors students.A six week rotation for final year was designed implemented 2010 involve them development, delivery...
<h3>Importance</h3> Based on contemporary estimates in the US, evidence-based therapies for cardiovascular risk reduction are generally underused among patients with type 2 diabetes and atherosclerotic disease (ASCVD). <h3>Objective</h3> To determine use of preventive a broad US population ASCVD. <h3>Design, Setting, Participants</h3> This multicenter cohort study used health system–level aggregated data within National Patient-Centered Clinical Research Network, including 12 systems....
Obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), non-high-density (non-HDL-C), particles, and apolipoproteins, when added to high-intensity statin in patients with dyslipidemia.To evaluate the safety lipid-altering efficacy of obicetrapib plus ezetimibe combination therapy as an adjunct therapy.This double-blind, randomized, phase 2 trial administered 10 mg (n = 40), 39), or placebo 40) for 12 weeks LDL-C >70...
Androgen deprivation therapy is the cornerstone of treatment for patients with advanced prostate cancer. Meta-analysis small, oncology-focused trials suggest gonadotropin-releasing hormone (GnRH) antagonists may be associated fewer adverse cardiovascular outcomes compared GnRH agonists.
Obicetrapib, a novel, selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), LDL particles, apolipoprotein (Apo) B, and lipoprotein(a) [Lp(a)] increases high-density (HDL-C) when added to statins with or without ezetimibe. By substantially reducing LDL-C, obicetrapib has the potential lower atherogenic lipoproteins in patients atherosclerotic cardiovascular disease (ASCVD) heterozygous familial hypercholesterolemia (HeFH) whose...
Importance The ATP citrate lyase (ACL) inhibitor, bempedoic acid, reduces low-density lipoprotein cholesterol (LDL-C) level and major adverse cardiovascular events (MACE) by 13% in patients at high risk with intolerance of statin high-intensity medications. effects acid on total remain unknown. Objective To determine the impact incidence MACE. Design, Setting, Participants Included this prespecified analysis Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes...